Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA) SAN CARLOS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety ...

BARCELONA, Spain, April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report on Form 20-F provides investors with an overview of the company's governance practices, including information about the B ...

Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ◻ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR ...

The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols' leadership in plasma therapeutics, producing about 40% of the company's total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants while its envir ...

Grifols' in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalent CE mark for Grifols' Procleix ArboPlex Assay reinforces the company's leadership in transfusion medicine and commitment to ensuring the safety of the world's blood supply BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols ...

Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Nuria Pascual Thomas Glanzmann Let me now walk you through how we are meeting our other commitments. Q3 was another quarter of strong revenue growth, where we also delivered a 25.1% adjusted EBITDA margin, which is a significant improvement of 480 basis points compared to Q4 '22 margin. The revenue growth was primarily driven by biopharma and our flagship franchises, immunoglobulin and albumin, and we expect that moment ...

Victor Grifols Deu Okay. Thank you. We have now on the line Tom Jones from Berenberg. Hi, Tom. Alfredo Arroyo Nuria Pascual Nuria Pascual Victor Grifols Deu Thank you. And next question coming from Alvaro Lenze from Alantra Equities. Alvaro? Victor Grifols Deu Okay. We have a question from - coming from JoaquÃn GarcÃa-Quirós from JB Capital. Hi, JoaquÃn. Victor Grifols Deu Great. We have a couple of follow-up questions. First from - he was the first to be again nonetheless Tom, I think you have something el ...

Solid start to the year, while advancing on the turnaround plan backed by a new performance culture | --- | --- | --- | --- | --- | |-------|--------------------------------------------------------|-------------------------------------------------------------------------------|-------|------------------------------------------------------------------| | | Governance | Operational Improvement Plan | | Accelerating deleverage | | • | Formalized roles and responsibilities within SELT | • Deployed 80%+ of the E ...

Nuria Pascual Victor Grifols Deu Thank you. Thank you, Victor and thank you, Guilherme. Now is the turn for Berenberg, Tom Jones. Hi, Tom. We have lost Tom? Thomas Glanzmann Tom Jones Tom Jones Jaime Escribano Hello, Jaime. I'll take the first one. We are, let's say grams wise being sold for us compared to pre-to-'19. We are not yet there, but we are very close after our plasma recovery. Jaime Escribano First of all from the cash savings perspective, we expect it and we see those basis after a significant d ...

Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ◻ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) O ...